This difference in the effect size could be due to tumor-specific factors, incomplete cefepime effects on PDL1-regulated DNA damage repair molecules, incomplete PDL1 depletion, or a requirement for immune contributions, which could be seen in vivo. The gene discussed is CD274; the disease is neoplasm.